669.5K XNYS Volume
XNYS 19 Mar, 2025 10:06 AM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Steven W. Eck | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 17.53 per share. | 26 Feb 2025 | 4,907 | 40,604 (0%) | 0% | 17.5 | 86,020 | Common Stock |
| Steven W. Eck | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 17.00 per share. | 26 Feb 2025 | 1,033 | 39,571 (0%) | 0% | 17 | 17,561 | Common Stock |
| James Bramwell | EVP Sales, Customer Excellence | Sale of securities on an exchange or to another person at price $ 17.00 per share. | 26 Feb 2025 | 774 | 86,605 (0%) | 0% | 17 | 13,158 | Common Stock |
| James Bramwell | EVP Sales, Customer Excellence | Sale of securities on an exchange or to another person at price $ 17.53 per share. | 26 Feb 2025 | 3,758 | 87,379 (0%) | 0% | 17.5 | 65,878 | Common Stock |
| Christophe Couturier | EVP, AMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.47 per share. | 24 Feb 2025 | 750 | 84,965 (0%) | 0% | 17.5 | 13,103 | Common Stock |
| Christophe Couturier | EVP, AMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.56 per share. | 24 Feb 2025 | 556 | 84,409 (0%) | 0% | 17.6 | 9,763 | Common Stock |
| Steven W. Eck | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.56 per share. | 24 Feb 2025 | 505 | 45,511 (0%) | 0% | 17.6 | 8,868 | Common Stock |
| Steven W. Eck | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.47 per share. | 24 Feb 2025 | 439 | 46,016 (0%) | 0% | 17.5 | 7,669 | Common Stock |
| Michael Stubblefield | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.47 per share. | 24 Feb 2025 | 6,800 | 1,452,991 (0%) | 0% | 17.5 | 118,796 | Common Stock |
| Michael Stubblefield | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.56 per share. | 24 Feb 2025 | 4,969 | 1,448,022 (0%) | 0% | 17.6 | 87,256 | Common Stock |
| James Bramwell | EVP Sales, Customer Excellence | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.47 per share. | 24 Feb 2025 | 2,181 | 91,720 (0%) | 0% | 17.5 | 38,102 | Common Stock |
| James Bramwell | EVP Sales, Customer Excellence | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.56 per share. | 24 Feb 2025 | 583 | 91,137 (0%) | 0% | 17.6 | 10,237 | Common Stock |
| Brittany Hankamer | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.56 per share. | 24 Feb 2025 | 369 | 49,595 (0%) | 0% | 17.6 | 6,480 | Common Stock |
| Brittany Hankamer | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.47 per share. | 24 Feb 2025 | 437 | 49,964 (0%) | 0% | 17.5 | 7,634 | Common Stock |
| James Bramwell | EVP Sales, Customer Excellence | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.30 per share. | 23 Feb 2025 | 3,443 | 93,901 (0%) | 0% | 17.3 | 59,564 | Common Stock |
| R. Brent Jones | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 103,878 | 103,878 | - | - | Stock Options (Right to Buy) | |
| R. Brent Jones | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 42,881 | 69,646 (0%) | 0% | 0 | Common Stock | |
| R. Brent Jones | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 37,164 | 106,810 (0%) | 0% | 0 | Common Stock | |
| Christophe Couturier | EVP, AMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.30 per share. | 20 Feb 2025 | 1,506 | 85,715 (0%) | 0% | 17.3 | 26,054 | Common Stock |
| Christophe Couturier | EVP, AMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 31,163 | 31,163 | - | - | Stock Options (Right to Buy) | |
| Christophe Couturier | EVP, AMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 12,864 | 87,221 (0%) | 0% | 0 | Common Stock | |
| Steven W. Eck | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.30 per share. | 20 Feb 2025 | 1,956 | 46,455 (0%) | 0% | 17.3 | 33,839 | Common Stock |
| Steven W. Eck | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 18,867 | 48,411 (0%) | 0% | 0 | Common Stock | |
| Michael Stubblefield | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 380,886 | 380,886 | - | - | Stock Options (Right to Buy) | |
| Michael Stubblefield | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 157,232 | 1,474,465 (0%) | 0% | 0 | Common Stock | |
| Michael Stubblefield | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.30 per share. | 20 Feb 2025 | 14,674 | 1,459,791 (0%) | 0% | 17.3 | 253,860 | Common Stock |
| Claudius Sokenu | EVP, Chief Legal & Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.30 per share. | 20 Feb 2025 | 2,318 | 58,080 (0%) | 0% | 17.3 | 40,101 | Common Stock |
| Claudius Sokenu | EVP, Chief Legal & Compliance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 21,440 | 60,398 (0%) | 0% | 0 | Common Stock | |
| Claudius Sokenu | EVP, Chief Legal & Compliance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 51,939 | 51,939 | - | - | Stock Options (Right to Buy) | |
| Brittany Hankamer | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.30 per share. | 20 Feb 2025 | 1,537 | 50,401 (0%) | 0% | 17.3 | 26,590 | Common Stock |
| Brittany Hankamer | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 17,152 | 51,938 (0%) | 0% | 0 | Common Stock | |
| Brittany Hankamer | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 41,551 | 41,551 | - | - | Stock Options (Right to Buy) | |
| Benoit Gourdier | EVP, Bioscience Production | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 86,565 | 86,565 | - | - | Stock Options (Right to Buy) | |
| Benoit Gourdier | EVP, Bioscience Production | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 35,734 | 76,924 (0%) | 0% | 0 | Common Stock | |
| Benoit Gourdier | EVP, Bioscience Production | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.30 per share. | 20 Feb 2025 | 2,842 | 74,082 (0%) | 0% | 17.3 | 49,167 | Common Stock |
| Louise Makin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2024 | 4,770 | 4,770 (0%) | 0% | 0 | Common Stock | |
| Benoit Gourdier | EVP, Bioscience Production | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.54 per share. | 02 Oct 2024 | 1,263 | 41,190 (0%) | 0% | 25.5 | 32,257 | Common Stock |
| Steven W. Eck | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 25.06 per share. | 05 Sep 2024 | 3,525 | 29,544 (0%) | 0% | 25.1 | 88,337 | Common Stock |
| Brittany Hankamer | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.07 per share. | 14 Aug 2024 | 180 | 34,786 (0%) | 0% | 25.1 | 4,513 | Common Stock |
| Steven W. Eck | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.75 per share. | 31 Jul 2024 | 1,337 | 33,069 (0%) | 0% | 26.8 | 35,765 | Common Stock |
| Christophe Couturier | EVP, AMEA | Sale of securities on an exchange or to another person at price $ 28.00 per share. | 30 Jul 2024 | 100 | 73,930 (0%) | 0% | 28 | 2,800 | Common Stock |
| Christophe Couturier | EVP, AMEA | Sale of securities on an exchange or to another person at price $ 27.00 per share. | 30 Jul 2024 | 10,000 | 74,030 (0%) | 0% | 27 | 270,000 | Common Stock |
| Claudius Sokenu | EVP, Chief Legal & Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.37 per share. | 24 Jul 2024 | 3,122 | 38,958 (0%) | 0% | 22.4 | 69,839 | Common Stock |
| Kitty Sahin | EVP, Strategy&Corp Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.74 per share. | 18 Jul 2024 | 3,931 | 42,274 (0%) | 0% | 20.7 | 81,529 | Common Stock |
| Corey Walker | President Laboratory Solutions | 21 Jun 2024 | 70,462 | 70,462 | - | - | Stock Options (Right to Buy) | ||
| Corey Walker | President Laboratory Solutions | 21 Jun 2024 | 28,254 | 28,254 (0%) | 0% | 0 | Common Stock | ||
| Joseph R. Massaro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 8,477 | 26,938 (0%) | 0% | 0 | Common Stock | |
| Gregory L. Summe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 8,477 | 41,011 (0%) | 0% | 0 | Common Stock | |
| Jonathan M. Peacock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 8,477 | 194,624 (0%) | 0% | 0 | Common Stock | |
| Michael Severino | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 8,477 | 43,451 (0%) | 0% | 0 | Common Stock | |
| Juan Andres | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 8,477 | 48,380 (0%) | 0% | 0 | Common Stock | |
| Mala Murthy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 8,477 | 27,109 (0%) | 0% | 0 | Common Stock | |
| Lan Kang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 8,477 | 30,215 (0%) | 0% | 0 | Common Stock | |
| John Carethers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 8,477 | 28,758 (0%) | 0% | 0 | Common Stock | |
| Randy Lee Stone | EVP, Laboratory Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.60 per share. | 16 Apr 2024 | 6,762 | 68,105 (0%) | 0% | 24.6 | 166,345 | Common Stock |
| Christophe Couturier | EVP, AMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.87 per share. | 05 Apr 2024 | 569 | 83,320 (0%) | 0% | 25.9 | 14,720 | Common Stock |
| Steven W. Eck | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 25.63 per share. | 08 Mar 2024 | 3,685 | 34,406 (0%) | 0% | 25.6 | 94,447 | Common Stock |
| Christophe Couturier | EVP, AMEA | Sale of securities on an exchange or to another person at price $ 24.53 per share. | 29 Feb 2024 | 13,074 | 83,889 (0%) | 0% | 24.5 | 320,705 | Common Stock |
| James Bramwell | EVP Sales, Customer Excellence | Sale of securities on an exchange or to another person at price $ 24.52 per share. | 29 Feb 2024 | 4,910 | 96,233 (0%) | 0% | 24.5 | 120,393 | Common Stock |
| Kitty Sahin | EVP, Strategy&Corp Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.35 per share. | 24 Feb 2024 | 1,059 | 33,885 (0%) | 0% | 24.4 | 25,787 | Common Stock |
| Sahin Kitty | EVP, Strategy&Corp Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 30,122 | 30,122 | - | - | Stock Options (Right to Buy) | |
| Michael Stubblefield | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 107,802 | 1,219,553 (0%) | 0% | 0 | Common Stock | |
| Brent R. Jones | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 62,753 | 62,753 | - | - | Stock Options (Right to Buy) | |
| Hankamer Brittany | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.35 per share. | 23 Feb 2024 | 437 | 24,042 (0%) | 0% | 24.4 | 10,641 | Common Stock |
| Christophe Couturier | EVP, AMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 22,592 | 22,592 | - | - | Stock Options (Right to Buy) | |
| Hankamer Brittany | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.35 per share. | 23 Feb 2024 | 369 | 23,673 (0%) | 0% | 24.3 | 8,985 | Common Stock |
| Steven Eck W. | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 11,704 | 38,091 (0%) | 0% | 0 | Common Stock | |
| Lee Stone Randy | EVP, Proprietary Products | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 62,753 | 62,753 | - | - | Stock Options (Right to Buy) | |
| Hankamer Brittany | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 27,612 | 27,612 | - | - | Stock Options (Right to Buy) | |
| James Bramwell | EVP Sales, Customer Excellence | Sale of securities on an exchange or to another person at price $ 24.49 per share. | 23 Feb 2024 | 6,203 | 101,143 (0%) | 0% | 24.5 | 151,911 | Common Stock |
| Michael Stubblefield | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 263,558 | 263,558 | - | - | Stock Options (Right to Buy) | |
| Lee Stone Randy | EVP, Proprietary Products | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 25,667 | 74,867 (0%) | 0% | 0 | Common Stock | |
| Eck W. Steven | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.35 per share. | 23 Feb 2024 | 438 | 26,892 (0%) | 0% | 24.3 | 10,665 | Common Stock |
| Couturier Christophe | EVP, AMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 9,240 | 96,963 (0%) | 0% | 0 | Common Stock | |
| Hankamer Brittany | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.35 per share. | 23 Feb 2024 | 421 | 24,479 (0%) | 0% | 24.3 | 10,251 | Common Stock |
| Benoit Gourdier | EVP, Biopharma Production | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 25,667 | 42,453 (0%) | 0% | 0 | Common Stock | |
| W. Eck Steven | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.35 per share. | 23 Feb 2024 | 422 | 27,330 (0%) | 0% | 24.4 | 10,276 | Common Stock |
| Brent R. Jones | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 25,667 | 25,667 (0%) | 0% | 0 | Common Stock | |
| Eck Steven W. | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.35 per share. | 23 Feb 2024 | 505 | 26,387 (0%) | 0% | 24.4 | 12,297 | Common Stock |
| Claudius Sokenu | EVP, Chief Legal & Compliance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 42,674 | 42,674 | - | - | Stock Options (Right to Buy) | |
| Benoit Gourdier | EVP, Biopharma Production | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 62,753 | 62,753 | - | - | Stock Options (Right to Buy) | |
| James Bramwell | EVP Sales, Customer Excellence | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 20,533 | 107,346 (0%) | 0% | 0 | Common Stock | |
| Kitty Sahin | EVP, Strategy&Corp Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 12,320 | 46,205 (0%) | 0% | 0 | Common Stock | |
| Claudius Sokenu | EVP, Chief Legal & Compliance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 17,453 | 42,080 (0%) | 0% | 0 | Common Stock | |
| James Bramwell | EVP Sales, Customer Excellence | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 50,204 | 50,204 | - | - | Stock Options (Right to Buy) | |
| Brittany Hankamer | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 11,293 | 34,966 (0%) | 0% | 0 | Common Stock | |
| Christophe Couturier | EVP, AMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.35 per share. | 22 Feb 2024 | 648 | 88,190 (0%) | 0% | 24.4 | 15,779 | Common Stock |
| Couturier Christophe | EVP, AMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 9,290 | 91,828 (0%) | 0% | 0 | Common Stock | |
| Stubblefield Michael | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 99,075 | 1,177,630 (0%) | 0% | 0 | Common Stock | |
| Christophe Couturier | EVP, AMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.59 per share. | 22 Feb 2024 | 2,574 | 89,254 (0%) | 0% | 24.6 | 63,295 | Common Stock |
| Stubblefield Michael | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.59 per share. | 22 Feb 2024 | 41,177 | 1,136,453 (0%) | 0% | 24.6 | 1,012,542 | Common Stock |
| Stubblefield Michael | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.35 per share. | 22 Feb 2024 | 7,422 | 1,129,031 (0%) | 0% | 24.4 | 180,726 | Common Stock |
| Michael Stubblefield | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.35 per share. | 22 Feb 2024 | 9,595 | 1,119,436 (0%) | 0% | 24.3 | 233,638 | Common Stock |
| James Bramwell | EVP Sales, Customer Excellence | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.35 per share. | 22 Feb 2024 | 511 | 86,813 (0%) | 0% | 24.4 | 12,443 | Common Stock |
| Bramwell James | EVP Sales, Customer Excellence | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.59 per share. | 22 Feb 2024 | 2,842 | 89,848 (0%) | 0% | 24.6 | 69,885 | Common Stock |
| Stubblefield Michael | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.35 per share. | 22 Feb 2024 | 7,685 | 1,111,751 (0%) | 0% | 24.4 | 187,130 | Common Stock |
| Christophe Couturier | EVP, AMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.35 per share. | 22 Feb 2024 | 416 | 88,838 (0%) | 0% | 24.4 | 10,130 | Common Stock |
| Couturier Christophe | EVP, AMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.35 per share. | 22 Feb 2024 | 467 | 87,723 (0%) | 0% | 24.3 | 11,371 | Common Stock |
| James Bramwell | EVP Sales, Customer Excellence | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.35 per share. | 22 Feb 2024 | 1,955 | 87,324 (0%) | 0% | 24.3 | 47,604 | Common Stock |
| James Bramwell | EVP Sales, Customer Excellence | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 7,432 | 92,690 (0%) | 0% | 0 | Common Stock | |
| James Bramwell | EVP Sales, Customer Excellence | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.35 per share. | 22 Feb 2024 | 569 | 89,279 (0%) | 0% | 24.3 | 13,855 | Common Stock |
| Stubblefield Michael | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.05 per share. | 20 Feb 2024 | 9,711 | 1,078,555 (0%) | 0% | 24.1 | 233,550 | Common Stock |
| Steven Eck W. | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.05 per share. | 20 Feb 2024 | 435 | 27,752 (0%) | 0% | 24.1 | 10,462 | Common Stock |
| Bramwell James | EVP Sales, Customer Excellence | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.05 per share. | 20 Feb 2024 | 1,216 | 85,258 (0%) | 0% | 24.1 | 29,245 | Common Stock |
| Christophe Couturier | EVP, AMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.05 per share. | 20 Feb 2024 | 1,392 | 82,538 (0%) | 0% | 24.1 | 33,478 | Common Stock |
| Hankamer Brittany | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.05 per share. | 20 Feb 2024 | 289 | 24,900 (0%) | 0% | 24.0 | 6,950 | Common Stock |
| Sheri Lewis | EVP, Global Ops & Supply Chain | 31 Dec 2023 | 4,556 | 70,692 (0%) | 0% | 22.8 | 104,013 | Common Stock | |
| Benoit Gourdier | EVP, Biopharma Production | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2023 | 39,281 | 39,281 | - | - | Stock Options (Right to Buy) | |
| Benoit Gourdier | EVP, Biopharma Production | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2023 | 16,786 | 16,786 (0%) | 0% | 0 | Common Stock | |
| Steven W. Eck | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 20.64 per share. | 07 Sep 2023 | 7,577 | 28,187 (0%) | 0% | 20.6 | 156,389 | Common Stock |
| Brittany Hankamer | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.70 per share. | 05 Sep 2023 | 309 | 25,189 (0%) | 0% | 21.7 | 6,705 | Common Stock |
| Frederic Vanderhaegen | EVP, Americas and Europe | Sale of securities on an exchange or to another person at price $ 21.47 per share. | 25 Aug 2023 | 25,000 | 160,735 (0%) | 0% | 21.5 | 536,750 | Common Stock |
| R. Brent Jones | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2023 | 295,559 | 295,559 | - | - | Stock Options (Right to Buy) | |
| Steven W. Eck | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 14,584 | 35,764 (0%) | 0% | 0 | Common Stock | |
| Kitty Sahin | EVP, Strategy&Corp Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.01 per share. | 18 Jul 2023 | 3,931 | 34,944 (0%) | 0% | 21.0 | 82,590 | Common Stock |
| Michael Stubblefield | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 26 May 2023 | 40,000 | 1,032,937 (0%) | 0% | 0 | Common Stock | |
| Michael Stubblefield | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 26 May 2023 | 40,000 | 469,500 (0%) | 0% | 0 | Common Stock | |
| Thomas A. Szlosek | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.28 per share. | 17 May 2023 | 23,261 | 77,489 (0%) | 0% | 20.3 | 471,733 | Common Stock |
| Christophe Couturier | EVP, AMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.28 per share. | 17 May 2023 | 15,706 | 82,944 (0%) | 0% | 20.3 | 318,518 | Common Stock |
| Steven W. Eck | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.28 per share. | 17 May 2023 | 553 | 21,180 (0%) | 0% | 20.3 | 11,215 | Common Stock |
| Michael Stubblefield | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.28 per share. | 17 May 2023 | 106,200 | 1,172,937 (0%) | 0% | 20.3 | 2,153,736 | Common Stock |
| James Bramwell | EVP, Strategic Partners | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.28 per share. | 17 May 2023 | 18,917 | 85,393 (0%) | 0% | 20.3 | 383,637 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.28 per share. | 17 May 2023 | 19,683 | 89,032 (0%) | 0% | 20.3 | 399,171 | Common Stock |
| Justin Miller | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.28 per share. | 17 May 2023 | 12,449 | 93,336 (0%) | 0% | 20.3 | 252,466 | Common Stock |
| Frederic Vanderhaegen | EVP, Americas and Europe | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.28 per share. | 17 May 2023 | 2,210 | 185,735 (0%) | 0% | 20.3 | 44,819 | Common Stock |
| Joseph R. Massaro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 9,808 | 18,461 (0%) | 0% | 0 | Common Stock | |
| Gregory L. Summe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 9,808 | 32,534 (0%) | 0% | 0 | Common Stock | |
| Jonathan M. Peacock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 9,808 | 186,147 (0%) | 0% | 0 | Common Stock | |
| Michael Severino | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 9,808 | 34,974 (0%) | 0% | 0 | Common Stock | |
| Christi Shaw | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 9,808 | 36,271 (0%) | 0% | 0 | Common Stock | |
| Juan Andres | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 9,808 | 39,903 (0%) | 0% | 0 | Common Stock | |
| Mala Murthy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 9,808 | 18,632 (0%) | 0% | 0 | Common Stock | |
| Lan Kang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 9,808 | 21,738 (0%) | 0% | 0 | Common Stock | |
| John Carethers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 9,808 | 20,281 (0%) | 0% | 0 | Common Stock | |
| Christophe Couturier | EVP, AMEA | Sale of securities on an exchange or to another person at price $ 21.18 per share. | 11 Apr 2023 | 1,498 | 98,650 (0%) | 0% | 21.2 | 31,728 | Common Stock |
| Christophe Couturier | EVP, AMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.82 per share. | 05 Apr 2023 | 569 | 100,148 (0%) | 0% | 20.8 | 11,847 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 03 Mar 2023 | 3,914 | 108,715 (0%) | 0% | 25 | 97,850 | Common Stock |
| Christophe Couturier | EVP, AMEA | Sale of securities on an exchange or to another person at price $ 24.32 per share. | 28 Feb 2023 | 2,324 | 100,717 (0%) | 0% | 24.3 | 56,520 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 27 Feb 2023 | 3,059 | 112,629 (0%) | 0% | 25 | 76,475 | Common Stock |
| Kitty Sahin | EVP, Strategy&Corp Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 12,185 | 38,875 (0%) | 0% | 0 | Common Stock | |
| Kitty Sahin | EVP, Strategy&Corp Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 29,529 | 29,529 | - | - | Stock Options (Right to Buy) | |
| Thomas A. Szlosek | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.59 per share. | 23 Feb 2023 | 2,082 | 88,790 (0%) | 0% | 24.6 | 51,196 | Common Stock |
| Thomas A. Szlosek | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 22,339 | 106,893 (0%) | 0% | 0 | Common Stock | |
| Thomas A. Szlosek | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.62 per share. | 23 Feb 2023 | 2,040 | 104,853 (0%) | 0% | 24.6 | 50,225 | Common Stock |
| Thomas A. Szlosek | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 54,135 | 54,135 | - | - | Stock Options (Right to Buy) | |
| Christophe Couturier | EVP, AMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.62 per share. | 23 Feb 2023 | 467 | 103,041 (0%) | 0% | 24.6 | 11,498 | Common Stock |
| Christophe Couturier | EVP, AMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 22,149 | 22,149 | - | - | Stock Options (Right to Buy) | |
| Christophe Couturier | EVP, AMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.59 per share. | 23 Feb 2023 | 416 | 97,448 (0%) | 0% | 24.6 | 10,229 | Common Stock |
| Christophe Couturier | EVP, AMEA | Sale of securities on an exchange or to another person at price $ 24.24 per share. | 23 Feb 2023 | 3,078 | 94,370 (0%) | 0% | 24.2 | 74,611 | Common Stock |
| Christophe Couturier | EVP, AMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 9,138 | 103,508 (0%) | 0% | 0 | Common Stock | |
| Steven W. Eck | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 12,963 | 12,963 | - | - | Stock Options (Right to Buy) | |
| Steven W. Eck | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.59 per share. | 23 Feb 2023 | 421 | 16,891 (0%) | 0% | 24.6 | 10,352 | Common Stock |
| Steven W. Eck | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 5,347 | 22,238 (0%) | 0% | 0 | Common Stock | |
| Steven W. Eck | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.62 per share. | 23 Feb 2023 | 505 | 21,733 (0%) | 0% | 24.6 | 12,433 | Common Stock |
| Michael Stubblefield | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 239,915 | 239,915 | - | - | Stock Options (Right to Buy) | |
| Michael Stubblefield | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.59 per share. | 23 Feb 2023 | 7,422 | 1,187,818 (0%) | 0% | 24.6 | 182,507 | Common Stock |
| Michael Stubblefield | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 99,004 | 1,286,822 (0%) | 0% | 0 | Common Stock | |
| Michael Stubblefield | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.62 per share. | 23 Feb 2023 | 7,685 | 1,279,137 (0%) | 0% | 24.6 | 189,205 | Common Stock |
| James Bramwell | EVP, Americas | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.59 per share. | 23 Feb 2023 | 569 | 84,513 (0%) | 0% | 24.6 | 13,992 | Common Stock |
| James Bramwell | EVP, Americas | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 20,308 | 104,821 (0%) | 0% | 0 | Common Stock | |
| James Bramwell | EVP, Americas | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.62 per share. | 23 Feb 2023 | 511 | 104,310 (0%) | 0% | 24.6 | 12,581 | Common Stock |
| James Bramwell | EVP, Americas | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 49,215 | 49,215 | - | - | Stock Options (Right to Buy) | |
| Gerard Brophy | EVP, Biopharma Production | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 20,308 | 117,728 (0%) | 0% | 0 | Common Stock | |
| Gerard Brophy | EVP, Biopharma Production | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 49,215 | 49,215 | - | - | Stock Options (Right to Buy) | |
| Gerard Brophy | EVP, Biopharma Production | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.59 per share. | 23 Feb 2023 | 1,893 | 97,420 (0%) | 0% | 24.6 | 46,549 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.62 per share. | 23 Feb 2023 | 2,040 | 115,688 (0%) | 0% | 24.6 | 50,225 | Common Stock |
| Justin Miller | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.62 per share. | 23 Feb 2023 | 560 | 105,785 (0%) | 0% | 24.6 | 13,787 | Common Stock |
| Justin Miller | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 22,149 | 22,149 | - | - | Stock Options (Right to Buy) | |
| Justin Miller | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.59 per share. | 23 Feb 2023 | 468 | 97,207 (0%) | 0% | 24.6 | 11,508 | Common Stock |
| Justin Miller | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 9,138 | 106,345 (0%) | 0% | 0 | Common Stock | |
| Frederic Vanderhaegen | EVP, Americas and Europe | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.62 per share. | 23 Feb 2023 | 299 | 187,945 (0%) | 0% | 24.6 | 7,361 | Common Stock |
| Frederic Vanderhaegen | EVP, Americas and Europe | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.59 per share. | 23 Feb 2023 | 213 | 167,936 (0%) | 0% | 24.6 | 5,238 | Common Stock |
| Frederic Vanderhaegen | EVP, Americas and Europe | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 20,308 | 188,244 (0%) | 0% | 0 | Common Stock | |
| Frederic Vanderhaegen | EVP, Americas and Europe | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 49,215 | 49,215 | - | - | Stock Options (Right to Buy) | |
| Sheri Lewis | EVP, Global Ops & Supply Chain | 23 Feb 2023 | 12,185 | 76,588 (0%) | 0% | 0 | Common Stock | ||
| Sheri Lewis | EVP, Global Ops & Supply Chain | 23 Feb 2023 | 29,529 | 29,529 | - | - | Stock Options (Right to Buy) | ||
| Sheri Lewis | EVP, Global Ops & Supply Chain | 23 Feb 2023 | 970 | 64,403 (0%) | 0% | 24.6 | 23,852 | Common Stock | |
| Sheri Lewis | EVP, Global Ops & Supply Chain | 23 Feb 2023 | 1,340 | 75,248 (0%) | 0% | 24.6 | 32,991 | Common Stock | |
| Meghan Henson | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.62 per share. | 23 Feb 2023 | 800 | 40,184 (0%) | 0% | 24.6 | 19,696 | Common Stock |
| Meghan Henson | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 29,529 | 29,529 | - | - | Stock Options (Right to Buy) | |
| Meghan Henson | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.59 per share. | 23 Feb 2023 | 816 | 28,799 (0%) | 0% | 24.6 | 20,065 | Common Stock |
| Meghan Henson | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 12,185 | 40,984 (0%) | 0% | 0 | Common Stock | |
| Thomas A. Szlosek | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.54 per share. | 20 Feb 2023 | 4,253 | 90,872 (0%) | 0% | 24.5 | 104,369 | Common Stock |
| Christophe Couturier | EVP, AMEA | Sale of securities on an exchange or to another person at price $ 24.12 per share. | 20 Feb 2023 | 19,160 | 97,160 (0%) | 0% | 24.1 | 462,139 | Common Stock |
| Christophe Couturier | EVP, AMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.54 per share. | 20 Feb 2023 | 1,167 | 117,024 (0%) | 0% | 24.5 | 28,638 | Common Stock |
| Steven W. Eck | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.54 per share. | 20 Feb 2023 | 435 | 17,312 (0%) | 0% | 24.5 | 10,675 | Common Stock |
| Michael Stubblefield | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.54 per share. | 20 Feb 2023 | 15,026 | 1,195,240 (0%) | 0% | 24.5 | 368,738 | Common Stock |
| James Bramwell | EVP, Americas | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.54 per share. | 20 Feb 2023 | 1,066 | 85,082 (0%) | 0% | 24.5 | 26,160 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.54 per share. | 20 Feb 2023 | 3,072 | 99,313 (0%) | 0% | 24.5 | 75,387 | Common Stock |
| Justin Miller | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.54 per share. | 20 Feb 2023 | 1,167 | 97,675 (0%) | 0% | 24.5 | 28,638 | Common Stock |
| Frederic Vanderhaegen | EVP, Americas & Europe | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.54 per share. | 20 Feb 2023 | 398 | 168,149 (0%) | 0% | 24.5 | 9,767 | Common Stock |
| Michael Wondrasch | EVP & CIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.54 per share. | 20 Feb 2023 | 1,356 | 96,072 (0%) | 0% | 24.5 | 33,276 | Common Stock |
| Thomas A. Szlosek | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 53,636 | 148,761 (0%) | 0% | 0 | Common Stock | |
| Thomas A. Szlosek | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.90 per share. | 31 Jan 2023 | 24,187 | 124,574 (0%) | 0% | 23.9 | 578,069 | Common Stock |
| Christophe Couturier | EVP, AMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.90 per share. | 31 Jan 2023 | 7,658 | 118,191 (0%) | 0% | 23.9 | 183,026 | Common Stock |
| Christophe Couturier | EVP, AMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 26,818 | 125,849 (0%) | 0% | 0 | Common Stock | |
| Michael Stubblefield | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 223,482 | 1,301,406 (0%) | 0% | 0 | Common Stock | |
| Michael Stubblefield | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.90 per share. | 31 Jan 2023 | 91,140 | 1,210,266 (0%) | 0% | 23.9 | 2,178,246 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 38,737 | 128,945 (0%) | 0% | 0 | Common Stock | |
| Gerard Brophy | EVP, Biopharma Production | Sale of securities on an exchange or to another person at price $ 25.06 per share. | 31 Jan 2023 | 11,339 | 102,385 (0%) | 0% | 25.1 | 284,155 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.90 per share. | 31 Jan 2023 | 15,221 | 113,724 (0%) | 0% | 23.9 | 363,782 | Common Stock |
| Justin Miller | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.90 per share. | 31 Jan 2023 | 7,942 | 98,842 (0%) | 0% | 23.9 | 189,814 | Common Stock |
| Justin Miller | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 26,818 | 106,784 (0%) | 0% | 0 | Common Stock | |
| Frederic Vanderhaegen | EVP, Americas & Europe | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.90 per share. | 31 Jan 2023 | 2,515 | 168,547 (0%) | 0% | 23.9 | 60,109 | Common Stock |
| Frederic Vanderhaegen | EVP, Americas & Europe | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 44,669 | 171,062 (0%) | 0% | 0 | Common Stock | |
| Thomas A. Szlosek | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.09 per share. | 02 Jan 2023 | 8,313 | 109,395 (0%) | 0% | 21.1 | 175,321 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.09 per share. | 02 Jan 2023 | 6,727 | 90,208 (0%) | 0% | 21.1 | 141,872 | Common Stock |
| Frederic Vanderhaegen | EVP, Americas & Europe | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.09 per share. | 02 Jan 2023 | 1,017 | 126,363 (0%) | 0% | 21.1 | 21,449 | Common Stock |
| Sheri Lewis | EVP, Global Ops & Supply Chain | 31 Dec 2022 | 6,075 | 65,373 (0%) | 0% | 21.1 | 128,122 | Common Stock | |
| Meghan Henson | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.09 per share. | 31 Dec 2022 | 1,790 | 29,615 (0%) | 0% | 21.1 | 37,751 | Common Stock |
| Thomas A. Szlosek | EVP & CFO | Purchase of securities on an exchange or from another person at price $ 20.71 per share. | 16 Nov 2022 | 12,500 | 35,668 (0%) | 0% | 20.7 | 258,850 | Common Stock |
| Michael Stubblefield | Director, CEO | Purchase of securities on an exchange or from another person at price $ 20.95 per share. | 16 Nov 2022 | 15,000 | 429,500 (0%) | 0% | 21.0 | 314,250 | Common Stock |
| Frederic Vanderhaegen | EVP, Americas & Europe | Sale of securities on an exchange or to another person at price $ 31.61 per share. | 23 May 2022 | 39,000 | 126,764 (0%) | 0% | 31.6 | 1,232,790 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Sale of securities on an exchange or to another person at price $ 31.27 per share. | 20 May 2022 | 19,603 | 96,935 (0%) | 0% | 31.3 | 612,986 | Common Stock |
| Thomas A. Szlosek | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.33 per share. | 17 May 2022 | 23,261 | 140,260 (0%) | 0% | 31.3 | 728,767 | Common Stock |
| Christophe Couturier | EVP, AMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.33 per share. | 17 May 2022 | 16,212 | 98,348 (0%) | 0% | 31.3 | 507,922 | Common Stock |
| Steven W. Eck | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.33 per share. | 17 May 2022 | 573 | 17,747 (0%) | 0% | 31.3 | 17,952 | Common Stock |
| Michael Stubblefield | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.33 per share. | 17 May 2022 | 108,700 | 1,189,841 (0%) | 0% | 31.3 | 3,405,571 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.33 per share. | 17 May 2022 | 19,683 | 116,538 (0%) | 0% | 31.3 | 616,668 | Common Stock |
| Justin Miller | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.33 per share. | 17 May 2022 | 12,935 | 79,312 (0%) | 0% | 31.3 | 405,254 | Common Stock |
| Frederic Vanderhaegen | EVP, Americas & Europe | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.33 per share. | 17 May 2022 | 2,210 | 165,764 (0%) | 0% | 31.3 | 69,239 | Common Stock |
| Joseph R. Massaro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 6,693 | 8,653 (0%) | 0% | 0 | Common Stock | |
| Gregory L. Summe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 6,693 | 22,726 (0%) | 0% | 0 | Common Stock | |
| Jonathan M. Peacock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 6,693 | 176,339 (0%) | 0% | 0 | Common Stock | |
| Michael Severino | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 6,693 | 25,166 (0%) | 0% | 0 | Common Stock | |
| Matthew Holt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 6,693 | 7,908 (0%) | 0% | 0 | Common Stock | |
| Christi Shaw | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 6,693 | 26,463 (0%) | 0% | 0 | Common Stock | |
| Juan Andres | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 6,693 | 30,095 (0%) | 0% | 0 | Common Stock | |
| Mala Murthy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 6,693 | 8,824 (0%) | 0% | 0 | Common Stock | |
| Lan Kang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 6,693 | 11,930 (0%) | 0% | 0 | Common Stock | |
| John Carethers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 6,693 | 10,473 (0%) | 0% | 0 | Common Stock | |
| Michael Stubblefield | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 04 May 2022 | 14,500 | 414,500 (0%) | 0% | 0 | Common Stock | |
| Michael Stubblefield | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 04 May 2022 | 14,500 | 1,298,541 (0%) | 0% | 0 | Common Stock | |
| Christophe Couturier | EVP, AMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.62 per share. | 05 Apr 2022 | 568 | 114,560 (0%) | 0% | 31.6 | 17,960 | Common Stock |
| Joseph R. Massaro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 1,215 | 1,960 (0%) | 0% | 0 | Common Stock | |
| Gregory L. Summe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 1,215 | 16,033 (0%) | 0% | 0 | Common Stock | |
| Jonathan M. Peacock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 1,215 | 169,646 (0%) | 0% | 0 | Common Stock | |
| Michael Severino | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 1,215 | 18,473 (0%) | 0% | 0 | Common Stock | |
| Matthew Holt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 1,215 | 1,215 (0%) | 0% | 0 | Common Stock | |
| Christi Shaw | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 1,215 | 19,770 (0%) | 0% | 0 | Common Stock | |
| Juan Andres | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 1,215 | 23,402 (0%) | 0% | 0 | Common Stock | |
| Mala Murthy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 1,215 | 2,131 (0%) | 0% | 0 | Common Stock | |
| Lan Kang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 1,215 | 5,237 (0%) | 0% | 0 | Common Stock | |
| John Carethers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 1,215 | 3,780 (0%) | 0% | 0 | Common Stock | |
| Rajiv K. Gupta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 1,215 | 780,562 (0%) | 0% | 0 | Common Stock | |
| Gerard Brophy | EVP, Biopharma Production | Sale of securities on an exchange or to another person at price $ 34.47 per share. | 01 Mar 2022 | 2,027 | 136,221 (0%) | 0% | 34.5 | 69,871 | Common Stock |
| Thomas A. Szlosek | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 48,079 | 48,079 | - | - | Stock Options (Right to Buy) | |
| Thomas A. Szlosek | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 16,621 | 254,789 (0%) | 0% | 0 | Common Stock | |
| Thomas A. Szlosek | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.39 per share. | 23 Feb 2022 | 2,043 | 252,746 (0%) | 0% | 35.4 | 72,302 | Common Stock |
| Christophe Couturier | EVP, AMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 6,044 | 115,595 (0%) | 0% | 0 | Common Stock | |
| Christophe Couturier | EVP, AMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.39 per share. | 23 Feb 2022 | 467 | 115,128 (0%) | 0% | 35.4 | 16,527 | Common Stock |
| Christophe Couturier | EVP, AMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 17,483 | 17,483 | - | - | Stock Options (Right to Buy) | |
| Steven W. Eck | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 5,138 | 18,838 (0%) | 0% | 0 | Common Stock | |
| Steven W. Eck | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.39 per share. | 23 Feb 2022 | 518 | 18,320 (0%) | 0% | 35.4 | 18,332 | Common Stock |
| Steven W. Eck | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 14,858 | 14,858 | - | - | Stock Options (Right to Buy) | |
| Michael Stubblefield | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 69,885 | 1,320,907 (0%) | 0% | 0 | Common Stock | |
| Michael Stubblefield | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 202,143 | 202,143 | - | - | Stock Options (Right to Buy) | |
| Michael Stubblefield | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.39 per share. | 23 Feb 2022 | 7,866 | 1,313,041 (0%) | 0% | 35.4 | 278,378 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Sale of securities on an exchange or to another person at price $ 33.79 per share. | 23 Feb 2022 | 3,059 | 125,181 (0%) | 0% | 33.8 | 103,364 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 15,110 | 140,291 (0%) | 0% | 0 | Common Stock | |
| Gerard Brophy | EVP, Biopharma Production | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.39 per share. | 23 Feb 2022 | 2,043 | 138,248 (0%) | 0% | 35.4 | 72,302 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 43,708 | 43,708 | - | - | Stock Options (Right to Buy) | |
| Justin Miller | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 6,800 | 92,830 (0%) | 0% | 0 | Common Stock | |
| Justin Miller | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 19,664 | 19,664 | - | - | Stock Options (Right to Buy) | |
| Justin Miller | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.39 per share. | 23 Feb 2022 | 583 | 92,247 (0%) | 0% | 35.4 | 20,632 | Common Stock |
| Frederic Vanderhaegen | EVP, Americas & Europe | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 43,708 | 43,708 | - | - | Stock Options (Right to Buy) | |
| Frederic Vanderhaegen | EVP, Americas & Europe | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 15,110 | 168,190 (0%) | 0% | 0 | Common Stock | |
| Frederic Vanderhaegen | EVP, Americas & Europe | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.39 per share. | 23 Feb 2022 | 216 | 167,974 (0%) | 0% | 35.4 | 7,644 | Common Stock |
| Sheri Lewis | EVP, Global Ops & Supply Chain | 23 Feb 2022 | 9,822 | 72,585 (0%) | 0% | 0 | Common Stock | ||
| Sheri Lewis | EVP, Global Ops & Supply Chain | 23 Feb 2022 | 1,137 | 71,448 (0%) | 0% | 35.4 | 40,238 | Common Stock | |
| Sheri Lewis | EVP, Global Ops & Supply Chain | 23 Feb 2022 | 28,406 | 28,406 | - | - | Stock Options (Right to Buy) | ||
| Meghan Henson | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 8,311 | 32,336 (0%) | 0% | 0 | Common Stock | |
| Meghan Henson | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.39 per share. | 23 Feb 2022 | 931 | 31,405 (0%) | 0% | 35.4 | 32,948 | Common Stock |
| Meghan Henson | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 24,035 | 24,035 | - | - | Stock Options (Right to Buy) | |
| Thomas A. Szlosek | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.00 per share. | 20 Feb 2022 | 4,040 | 238,168 (0%) | 0% | 34 | 137,360 | Common Stock |
| Christophe Couturier | EVP, AMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.00 per share. | 20 Feb 2022 | 1,267 | 109,551 (0%) | 0% | 34 | 43,078 | Common Stock |
| Steven W. Eck | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.00 per share. | 20 Feb 2022 | 448 | 13,700 (0%) | 0% | 34 | 15,232 | Common Stock |
| Michael Stubblefield | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.00 per share. | 20 Feb 2022 | 10,959 | 1,251,022 (0%) | 0% | 34 | 372,606 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.00 per share. | 20 Feb 2022 | 3,072 | 128,240 (0%) | 0% | 34 | 104,448 | Common Stock |
| Justin Miller | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.00 per share. | 20 Feb 2022 | 1,328 | 86,030 (0%) | 0% | 34 | 45,152 | Common Stock |
| Frederic Vanderhaegen | EVP, Europe | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.69 per share. | 20 Feb 2022 | 398 | 153,080 (0%) | 0% | 28.7 | 11,419 | Common Stock |
| Mark Christopher Murray | EVP, Biomaterials & AT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.50 per share. | 13 Jan 2022 | 918 | 18,680 (0%) | 0% | 37.5 | 34,425 | Common Stock |
| Thomas A. Szlosek | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.14 per share. | 02 Jan 2022 | 8,101 | 242,208 (0%) | 0% | 42.1 | 341,376 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.45 per share. | 02 Jan 2022 | 59,418 | 202,281 (0%) | 0% | 18.4 | 1,096,262 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Sale of securities on an exchange or to another person at price $ 38.65 per share. | 02 Jan 2022 | 11,551 | 131,312 (0%) | 0% | 38.6 | 446,446 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Sale of securities on an exchange or to another person at price $ 40.77 per share. | 02 Jan 2022 | 59,418 | 142,863 (0%) | 0% | 40.8 | 2,422,472 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2022 | 59,418 | 59,417 | - | - | Stock Options (Right to Buy) | |
| Gerard Brophy | EVP, Biopharma Production | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.14 per share. | 02 Jan 2022 | 6,516 | 142,863 (0%) | 0% | 42.1 | 274,584 | Common Stock |
| Frederic Vanderhaegen | EVP, Europe | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.14 per share. | 02 Jan 2022 | 1,017 | 153,478 (0%) | 0% | 42.1 | 42,856 | Common Stock |
| Michael Wondrasch | EVP & CIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.14 per share. | 02 Jan 2022 | 9,517 | 104,312 (0%) | 0% | 42.1 | 401,046 | Common Stock |
| Rajiv K. Gupta | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2021 | 100,000 | 779,347 (0%) | 0% | 0 | Common Stock | |
| Sheri Lewis | EVP, Global Ops & Supply Chain | 31 Dec 2021 | 4,093 | 62,763 (0%) | 0% | 42.1 | 172,479 | Common Stock | |
| Meghan Henson | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.14 per share. | 31 Dec 2021 | 1,877 | 24,025 (0%) | 0% | 42.1 | 79,097 | Common Stock |
| Christophe Couturier | EVP, AMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.21 per share. | 27 Dec 2021 | 10,184 | 120,681 (0%) | 0% | 23.2 | 236,371 | Common Stock |
| Christophe Couturier | EVP, AMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2021 | 10,184 | 96,901 | - | - | Stock Options (Right to Buy) | |
| Christophe Couturier | EVP, AMEA | Sale of securities on an exchange or to another person at price $ 41.63 per share. | 27 Dec 2021 | 10,184 | 110,497 (0%) | 0% | 41.6 | 423,960 | Common Stock |
| Christophe Couturier | EVP, AMEA | Sale of securities on an exchange or to another person at price $ 41.53 per share. | 21 Dec 2021 | 28,125 | 110,497 (0%) | 0% | 41.5 | 1,168,031 | Common Stock |
| Christophe Couturier | EVP, AMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.21 per share. | 21 Dec 2021 | 28,125 | 138,622 (0%) | 0% | 23.2 | 652,781 | Common Stock |
| Christophe Couturier | EVP, AMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.21 per share. | 21 Dec 2021 | 38,309 | 148,806 (0%) | 0% | 23.2 | 889,152 | Common Stock |
| Christophe Couturier | EVP, AMEA | Sale of securities on an exchange or to another person at price $ 41.00 per share. | 21 Dec 2021 | 38,309 | 110,497 (0%) | 0% | 41 | 1,570,669 | Common Stock |
| Christophe Couturier | EVP, AMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2021 | 28,125 | 107,085 | - | - | Stock Options (Right to Buy) | |
| Christophe Couturier | EVP, AMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2021 | 38,309 | 96,901 | - | - | Stock Options (Right to Buy) | |
| Christophe Couturier | EVP, AMEA | Sale of securities on an exchange or to another person at price $ 40.24 per share. | 08 Dec 2021 | 7,859 | 110,497 (0%) | 0% | 40.2 | 316,246 | Common Stock |
| Christophe Couturier | EVP, AMEA | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 08 Dec 2021 | 5,828 | 110,497 (0%) | 0% | 40 | 233,120 | Common Stock |
| Christophe Couturier | EVP, AMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.67 per share. | 08 Dec 2021 | 5,828 | 116,325 (0%) | 0% | 17.7 | 102,981 | Common Stock |
| Christophe Couturier | EVP, AMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2021 | 7,859 | 41,058 | - | - | Stock Options (Right to Buy) | |
| Christophe Couturier | EVP, AMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2021 | 5,828 | 48,917 | - | - | Stock Options (Right to Buy) | |
| Christophe Couturier | EVP, AMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.67 per share. | 08 Dec 2021 | 7,859 | 118,356 (0%) | 0% | 17.7 | 138,869 | Common Stock |
| Rajiv K. Gupta | Director | Sale of securities on an exchange or to another person at price $ 39.30 per share. | 01 Dec 2021 | 100,000 | 879,347 (0%) | 0% | 39.3 | 3,930,000 | Common Stock |
| Frederic Vanderhaegen | EVP, Europe | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.20 per share. | 11 Nov 2021 | 80,000 | 234,495 (0%) | 0% | 23.2 | 1,856,000 | Common Stock |
| Frederic Vanderhaegen | EVP, Europe | Sale of securities on an exchange or to another person at price $ 38.41 per share. | 11 Nov 2021 | 60,804 | 154,495 (0%) | 0% | 38.4 | 2,335,482 | Common Stock |
| Frederic Vanderhaegen | EVP, Europe | Sale of securities on an exchange or to another person at price $ 38.25 per share. | 11 Nov 2021 | 80,000 | 154,495 (0%) | 0% | 38.3 | 3,060,000 | Common Stock |
| Frederic Vanderhaegen | EVP, Europe | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2021 | 80,000 | 460,830 | - | - | Stock Options (Right to Buy) | |
| Joseph R. Massaro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2021 | 745 | 745 (0%) | 0% | 0 | Common Stock | |
| Rajiv K. Gupta | Director | Sale of securities on an exchange or to another person at price $ 40.31 per share. | 01 Nov 2021 | 100,000 | 979,347 (0%) | 0% | 40.3 | 4,031,000 | Common Stock |
| Mala Murthy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 916 | 916 (0%) | 0% | 0 | Common Stock | |
| Rajiv K. Gupta | Director | Sale of securities on an exchange or to another person at price $ 39.94 per share. | 01 Oct 2021 | 100,000 | 1,079,347 (0%) | 0% | 39.9 | 3,994,000 | Common Stock |
| Michael Stubblefield | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 42.37 per share. | 20 Sep 2021 | 141,300 | 1,261,981 (0%) | 0% | 42.4 | 5,986,881 | Common Stock |
| Rajiv K. Gupta | Director | Sale of securities on an exchange or to another person at price $ 39.45 per share. | 01 Sep 2021 | 100,000 | 1,179,347 (0%) | 0% | 39.5 | 3,945,000 | Common Stock |
| Steven W. Eck | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 40.08 per share. | 26 Aug 2021 | 17,383 | 14,148 (0%) | 0% | 40.1 | 696,711 | Common Stock |
| Rajiv K. Gupta | Director | Sale of securities on an exchange or to another person at price $ 38.81 per share. | 20 Aug 2021 | 100,000 | 1,279,347 (0%) | 0% | 38.8 | 3,881,000 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Sale of securities on an exchange or to another person at price $ 37.24 per share. | 30 Jul 2021 | 81,125 | 149,379 (0%) | 0% | 37.2 | 3,021,095 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2021 | 81,125 | 81,125 | - | - | Stock Options (Right to Buy) | |
| Gerard Brophy | EVP, Biopharma Production | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.20 per share. | 30 Jul 2021 | 81,125 | 230,504 (0%) | 0% | 23.2 | 1,882,100 | Common Stock |
| James Bramwell | EVP, Strategic Partners | Sale of securities on an exchange or to another person at price $ 37.00 per share. | 20 Jul 2021 | 6,112 | 79,899 (0%) | 0% | 37 | 226,144 | Common Stock |
| John Carethers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 2,565 | 2,565 (0%) | 0% | 0 | Common Stock | |
| Jo Natauri | Director | Purchase of securities on an exchange or from another person at price $ 36.33 per share. | 12 Jul 2021 | 300 | 557,656 (0%) | 0% | 36.3 | 10,900 | Common Stock, par value $0.01 per share |
| James Bramwell | EVP, Strategic Partners | Sale of securities on an exchange or to another person at price $ 35.64 per share. | 09 Jul 2021 | 12,221 | 86,011 (0%) | 0% | 35.6 | 435,556 | Common Stock |
| James Bramwell | EVP, Strategic Partners | Sale of securities on an exchange or to another person at price $ 35.56 per share. | 09 Jul 2021 | 6,110 | 98,232 (0%) | 0% | 35.6 | 217,272 | Common Stock |
| Christophe Couturier | EVP, AMEA | Sale of securities on an exchange or to another person at price $ 35.73 per share. | 28 Jun 2021 | 28,096 | 110,077 (0%) | 0% | 35.7 | 1,003,870 | Common Stock |
| Rajiv K. Gupta | Director | Sale of securities on an exchange or to another person at price $ 35.32 per share. | 25 Jun 2021 | 68,605 | 1,379,347 (0%) | 0% | 35.3 | 2,423,129 | Common Stock |
| Michael Stubblefield | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 32.48 per share. | 08 Jun 2021 | 42,512 | 1,403,281 (0%) | 0% | 32.5 | 1,380,790 | Common Stock |
| Michael Stubblefield | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2021 | 57,375 | 0 | - | - | Common Stock | |
| Michael Stubblefield | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2021 | 42,512 | 0 | - | - | Stock Options (Right to Buy) | |
| Michael Stubblefield | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2021 | 235,170 | 42,512 | - | - | Stock Options (Right to Buy) | |
| Michael Stubblefield | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2021 | 152,643 | 277,682 | - | - | Stock Options (Right to Buy) | |
| Michael Stubblefield | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 32.48 per share. | 08 Jun 2021 | 57,375 | 1,403,281 (0%) | 0% | 32.5 | 1,863,540 | Common Stock |
| Michael Stubblefield | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.19 per share. | 08 Jun 2021 | 57,375 | 1,460,656 (0%) | 0% | 4.2 | 240,401 | Common Stock |
| Michael Stubblefield | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.13 per share. | 08 Jun 2021 | 42,512 | 1,445,793 (0%) | 0% | 3.1 | 133,063 | Common Stock |
| Michael Stubblefield | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 32.03 per share. | 08 Jun 2021 | 235,170 | 1,403,281 (0%) | 0% | 32.0 | 7,532,495 | Common Stock |
| Michael Stubblefield | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.13 per share. | 08 Jun 2021 | 235,170 | 1,638,451 (0%) | 0% | 3.1 | 736,082 | Common Stock |
| Michael Stubblefield | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 32.04 per share. | 08 Jun 2021 | 152,643 | 1,403,281 (0%) | 0% | 32.0 | 4,890,682 | Common Stock |
| Michael Stubblefield | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.13 per share. | 08 Jun 2021 | 152,643 | 1,555,924 (0%) | 0% | 3.1 | 477,773 | Common Stock |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 May 2021 | 100,000 | 347,181 | - | - | Stock Options (Right to Buy) | |
| Devashish Ohri | EVP, IMEA | Sale of securities on an exchange or to another person at price $ 31.99 per share. | 27 May 2021 | 100,000 | 139,095 (0%) | 0% | 32.0 | 3,199,000 | Common Stock |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.21 per share. | 27 May 2021 | 100,000 | 239,095 (0%) | 0% | 23.2 | 2,321,000 | Common Stock |
| Devashish Ohri | EVP, IMEA | Sale of securities on an exchange or to another person at price $ 31.87 per share. | 26 May 2021 | 15,000 | 139,095 (0%) | 0% | 31.9 | 478,050 | Common Stock |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.21 per share. | 26 May 2021 | 15,000 | 154,095 (0%) | 0% | 23.2 | 348,150 | Common Stock |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 May 2021 | 15,000 | 447,181 | - | - | Stock Options (Right to Buy) | |
| Rajiv K. Gupta | Director | Sale of securities on an exchange or to another person at price $ 31.94 per share. | 26 May 2021 | 78,109 | 278,109 (0%) | 0% | 31.9 | 2,494,801 | Common Stock |
| Rajiv K. Gupta | Director | Sale of securities on an exchange or to another person at price $ 31.89 per share. | 26 May 2021 | 150,000 | 356,218 (0%) | 0% | 31.9 | 4,783,500 | Common Stock |
| Rajiv K. Gupta | Director | Sale of securities on an exchange or to another person at price $ 31.74 per share. | 24 May 2021 | 180,000 | 663,789 (0%) | 0% | 31.7 | 5,713,200 | Common Stock |
| Rajiv K. Gupta | Director | Sale of securities on an exchange or to another person at price $ 31.57 per share. | 24 May 2021 | 157,571 | 506,218 (0%) | 0% | 31.6 | 4,974,516 | Common Stock |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.67 per share. | 24 May 2021 | 9,124 | 148,219 (0%) | 0% | 17.7 | 161,221 | Common Stock |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 May 2021 | 9,124 | 27,372 | - | - | Stock Options (Right to Buy) | |
| Devashish Ohri | EVP, IMEA | Sale of securities on an exchange or to another person at price $ 31.75 per share. | 24 May 2021 | 9,124 | 139,095 (0%) | 0% | 31.8 | 289,687 | Common Stock |
| Michael Wondrasch | EVP & CIO | Sale of securities on an exchange or to another person at price $ 31.41 per share. | 21 May 2021 | 18,488 | 113,295 (0%) | 0% | 31.4 | 580,708 | Common Stock |
| Christophe Couturier | EVP, AMEA | Sale of securities on an exchange or to another person at price $ 31.13 per share. | 20 May 2021 | 25,010 | 138,173 (0%) | 0% | 31.1 | 778,561 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Sale of securities on an exchange or to another person at price $ 31.10 per share. | 20 May 2021 | 19,603 | 149,379 (0%) | 0% | 31.1 | 609,653 | Common Stock |
| Justin Miller | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 31.12 per share. | 20 May 2021 | 18,488 | 86,536 (0%) | 0% | 31.1 | 575,347 | Common Stock |
| Thomas A. Szlosek | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.90 per share. | 17 May 2021 | 23,261 | 249,394 (0%) | 0% | 30.9 | 718,765 | Common Stock |
| Christophe Couturier | EVP, AMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 17 May 2021 | 14,276 | 163,183 (0%) | 0% | 0 | Common Stock | |
| Steven W. Eck | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.90 per share. | 17 May 2021 | 553 | 31,531 (0%) | 0% | 30.9 | 17,088 | Common Stock |
| Michael Stubblefield | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.90 per share. | 17 May 2021 | 106,200 | 1,403,281 (0%) | 0% | 30.9 | 3,281,580 | Common Stock |
| James Bramwell | EVP, Strategic Partners | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.90 per share. | 17 May 2021 | 14,324 | 103,812 (0%) | 0% | 30.9 | 442,612 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.90 per share. | 17 May 2021 | 19,683 | 168,982 (0%) | 0% | 30.9 | 608,205 | Common Stock |
| Justin Miller | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.90 per share. | 17 May 2021 | 13,655 | 105,024 (0%) | 0% | 30.9 | 421,940 | Common Stock |
| Devashish Ohri | EVP, IMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.90 per share. | 17 May 2021 | 16,793 | 139,095 (0%) | 0% | 30.9 | 518,904 | Common Stock |
| Frederic Vanderhaegen | EVP, Europe | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.90 per share. | 17 May 2021 | 2,210 | 214,384 (0%) | 0% | 30.9 | 68,289 | Common Stock |
| Michael Wondrasch | EVP & CIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.90 per share. | 17 May 2021 | 13,655 | 131,783 (0%) | 0% | 30.9 | 421,940 | Common Stock |
| Devashish Ohri | EVP, IMEA | Sale or transfer of securities back to the company at price $ 31.50 per share. | 14 May 2021 | 25,000 | 155,888 (0%) | 0% | 31.5 | 787,500 | Common Stock |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.21 per share. | 14 May 2021 | 25,000 | 180,888 (0%) | 0% | 23.2 | 580,250 | Common Stock |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2021 | 25,000 | 462,181 | - | - | Stock Options (Right to Buy) | |
| Lan Kang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 4,022 | 4,022 (0%) | 0% | 0 | Common Stock | |
| Jo Natauri | Director | Other type of transaction at price $ 30.86 per share. | 11 May 2021 | 24,729,495 | 175,624 (0%) | 4% | 30.9 | 763,152,216 | Common Stock, par value $0.01 per share |
| Jo Natauri | Director | Other type of transaction at price $ 30.86 per share. | 11 May 2021 | 92,661 | 92,661 (0%) | 0% | 30.9 | 2,859,518 | Common Stock, par value $0.01 per share |
| Jo Natauri | Director | Sale of securities on an exchange or to another person at price $ 30.68 per share. | 11 May 2021 | 2,626,771 | 24,807,517 (4%) | 0% | 30.7 | 80,589,334 | Common Stock, par value $0.01 per share |
| Devashish Ohri | EVP, IMEA | Sale of securities on an exchange or to another person at price $ 32.58 per share. | 30 Apr 2021 | 53,649 | 155,888 (0%) | 0% | 32.6 | 1,747,884 | Common Stock |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.21 per share. | 30 Apr 2021 | 53,649 | 209,537 (0%) | 0% | 23.2 | 1,245,193 | Common Stock |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2021 | 53,649 | 487,181 | - | - | Stock Options (Right to Buy) | |
| James Bramwell | EVP, Strategic Partners | Sale of securities on an exchange or to another person at price $ 32.00 per share. | 12 Apr 2021 | 2,505 | 118,136 (0%) | 0% | 32 | 80,160 | Common Stock |
| Justin Miller | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.21 per share. | 12 Apr 2021 | 100,000 | 218,679 (0%) | 0% | 23.2 | 2,321,000 | Common Stock |
| Justin Miller | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2021 | 100,000 | 305,625 | - | - | Stock Options (Right to Buy) | |
| Justin Miller | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 31.75 per share. | 12 Apr 2021 | 2,895 | 118,679 (0%) | 0% | 31.7 | 91,916 | Common Stock |
| Justin Miller | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 33.21 per share. | 12 Apr 2021 | 100,000 | 118,679 (0%) | 0% | 33.2 | 3,321,000 | Common Stock |
| Devashish Ohri | EVP, IMEA | Sale of securities on an exchange or to another person at price $ 32.37 per share. | 12 Apr 2021 | 100,160 | 155,888 (0%) | 0% | 32.4 | 3,242,179 | Common Stock |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.60 per share. | 12 Apr 2021 | 100,160 | 256,048 (0%) | 0% | 1.6 | 160,256 | Common Stock |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2021 | 100,160 | 0 | - | - | Stock Options (Right to Buy) | |
| Frederic Vanderhaegen | EVP, Europe | Sale of securities on an exchange or to another person at price $ 31.83 per share. | 12 Apr 2021 | 17,075 | 216,594 (0%) | 0% | 31.8 | 543,497 | Common Stock |
| Frederic Vanderhaegen | EVP, Europe | Sale of securities on an exchange or to another person at price $ 31.75 per share. | 12 Apr 2021 | 10,000 | 233,669 (0%) | 0% | 31.8 | 317,500 | Common Stock |
| Christophe Couturier | EVP, AMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2021 | 8,267 | 177,459 (0%) | 0% | 0 | Common Stock | |
| Frederic Vanderhaegen | EVP, Europe | Sale of securities on an exchange or to another person at price $ 28.21 per share. | 09 Mar 2021 | 10,000 | 243,669 (0%) | 0% | 28.2 | 282,100 | Common Stock |
| Michael Wondrasch | EVP & CIO | Sale of securities on an exchange or to another person at price $ 28.71 per share. | 02 Mar 2021 | 3,036 | 145,438 (0%) | 0% | 28.7 | 87,164 | Common Stock |
| Rakesh Sachdev | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 7,236 | 32,841 (0%) | 0% | 0 | Common Stock | |
| Thomas A. Szlosek | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 16,281 | 272,655 (0%) | 0% | 0 | Common Stock | |
| Thomas A. Szlosek | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 52,693 | 52,693 | - | - | Stock Options (Right to Buy) | |
| Gregory L. Summe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 7,236 | 14,818 (0%) | 0% | 0 | Common Stock | |
| Jonathan M. Peacock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 7,236 | 168,431 (0%) | 0% | 0 | Common Stock | |
| Michael Severino | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 7,236 | 17,258 (0%) | 0% | 0 | Common Stock | |
| Christophe Couturier | EVP, Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 6,784 | 169,192 (0%) | 0% | 0 | Common Stock | |
| Christophe Couturier | EVP, Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 21,956 | 21,956 | - | - | Stock Options (Right to Buy) | |
| Christi Shaw | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 7,236 | 18,555 (0%) | 0% | 0 | Common Stock | |
| Steven W. Eck | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 19,906 | 19,906 | - | - | Stock Options (Right to Buy) | |
| Steven W. Eck | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 6,151 | 32,084 (0%) | 0% | 0 | Common Stock | |
| Juan Andres | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 7,236 | 22,187 (0%) | 0% | 0 | Common Stock | |
| Michael Stubblefield | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 234,192 | 234,192 | - | - | Stock Options (Right to Buy) | |
| Michael Stubblefield | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 72,359 | 1,509,481 (0%) | 0% | 0 | Common Stock | |
| James Bramwell | EVP, Strategic Partners | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 17,564 | 17,564 | - | - | Stock Options (Right to Buy) | |
| James Bramwell | EVP, Strategic Partners | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 5,427 | 120,641 (0%) | 0% | 0 | Common Stock | |
| Gerard Brophy | EVP, Biopharma Production | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 16,281 | 188,665 (0%) | 0% | 0 | Common Stock | |
| Gerard Brophy | EVP, Biopharma Production | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 52,693 | 52,693 | - | - | Stock Options (Right to Buy) | |
| Justin Miller | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 8,140 | 121,574 (0%) | 0% | 0 | Common Stock | |
| Justin Miller | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 26,347 | 26,347 | - | - | Stock Options (Right to Buy) | |
| Devashish Ohri | EVP, IMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 17,564 | 17,564 | - | - | Stock Options (Right to Buy) | |
| Devashish Ohri | EVP, IMEA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 5,427 | 155,888 (0%) | 0% | 0 | Common Stock | |
| Frederic Vanderhaegen | EVP, Europe | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 52,693 | 52,693 | - | - | Stock Options (Right to Buy) | |
| Frederic Vanderhaegen | EVP, Europe | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 16,281 | 253,669 (0%) | 0% | 0 | Common Stock | |
| Michael Wondrasch | EVP & CIO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 8,140 | 148,474 (0%) | 0% | 0 | Common Stock | |
| Michael Wondrasch | EVP & CIO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 26,347 | 26,347 | - | - | Stock Options (Right to Buy) | |
| Mark Christopher Murray | EVP, Biomaterials & AT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 8,140 | 19,598 (0%) | 0% | 0 | Common Stock | |
| Mark Christopher Murray | EVP, Biomaterials & AT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 26,347 | 26,347 | - | - | Stock Options (Right to Buy) | |
| Sven Henrichwark | EVP, APAC Region | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 17,564 | 17,564 | - | - | Stock Options (Right to Buy) | |
| Sven Henrichwark | EVP, APAC Region | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 5,427 | 19,802 (0%) | 0% | 0 | Common Stock | |
| Sheri Lewis | EVP, Global Ops & Supply Chain | 25 Feb 2021 | 13,567 | 66,856 (0%) | 0% | 0 | Common Stock | ||
| Sheri Lewis | EVP, Global Ops & Supply Chain | 25 Feb 2021 | 43,911 | 43,911 | - | - | Stock Options (Right to Buy) | ||
| Meghan Henson | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 8,140 | 25,902 (0%) | 0% | 0 | Common Stock | |
| Meghan Henson | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 26,347 | 26,347 | - | - | Common Stock | |
| Rajiv K. Gupta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 7,236 | 1,447,952 (0%) | 0% | 0 | Common Stock | |
| Steven W. Eck | SVP & Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2021 | 8,550 | 28,532 (0%) | 0% | 0 | Common Stock | |
| Steven W. Eck | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.94 per share. | 24 Feb 2021 | 2,577 | 25,955 (0%) | 0% | 27.9 | 72,001 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Sale of securities on an exchange or to another person at price $ 27.93 per share. | 24 Feb 2021 | 3,059 | 172,384 (0%) | 0% | 27.9 | 85,438 | Common Stock |
| Thomas A. Szlosek | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.69 per share. | 22 Feb 2021 | 2,980 | 256,374 (0%) | 0% | 28.7 | 85,496 | Common Stock |
| Christophe Couturier | EVP, Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.69 per share. | 22 Feb 2021 | 1,313 | 162,408 (0%) | 0% | 28.7 | 37,670 | Common Stock |
| Steven W. Eck | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.69 per share. | 22 Feb 2021 | 449 | 19,982 (0%) | 0% | 28.7 | 12,882 | Common Stock |
| Michael Stubblefield | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.69 per share. | 22 Feb 2021 | 10,141 | 1,437,122 (0%) | 0% | 28.7 | 290,945 | Common Stock |
| James Bramwell | EVP, Strategic Partners | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.69 per share. | 22 Feb 2021 | 1,216 | 115,214 (0%) | 0% | 28.7 | 34,887 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.69 per share. | 22 Feb 2021 | 3,072 | 175,443 (0%) | 0% | 28.7 | 88,136 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Sale of securities on an exchange or to another person at price $ 28.62 per share. | 22 Feb 2021 | 19,769 | 175,443 (0%) | 0% | 28.6 | 565,789 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2021 | 19,769 | 59,306 | - | - | Stock Options (Right to Buy) | |
| Gerard Brophy | EVP, Biopharma Production | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.67 per share. | 22 Feb 2021 | 19,769 | 195,212 (0%) | 0% | 17.7 | 349,318 | Common Stock |
| Justin Miller | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.69 per share. | 22 Feb 2021 | 1,350 | 113,434 (0%) | 0% | 28.7 | 38,732 | Common Stock |
| Devashish Ohri | EVP, IMEA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.69 per share. | 22 Feb 2021 | 1,210 | 150,461 (0%) | 0% | 28.7 | 34,715 | Common Stock |
| Frederic Vanderhaegen | EVP, Europe | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.69 per share. | 22 Feb 2021 | 398 | 237,388 (0%) | 0% | 28.7 | 11,419 | Common Stock |
| Michael Wondrasch | EVP & CIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.69 per share. | 22 Feb 2021 | 1,209 | 140,334 (0%) | 0% | 28.7 | 34,686 | Common Stock |
| Michael Wondrasch | EVP & CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.20 per share. | 05 Feb 2021 | 40,000 | 181,543 (0%) | 0% | 23.2 | 928,000 | Common Stock |
| Michael Wondrasch | EVP & CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 40,000 | 230,415 | - | - | Stock Options (Right to Buy) | |
| Michael Wondrasch | EVP & CIO | Sale of securities on an exchange or to another person at price $ 29.77 per share. | 05 Feb 2021 | 40,000 | 141,543 (0%) | 0% | 29.8 | 1,190,800 | Common Stock |
| Michael Wondrasch | EVP & CIO | Sale of securities on an exchange or to another person at price $ 29.77 per share. | 05 Feb 2021 | 9,468 | 141,543 (0%) | 0% | 29.8 | 281,862 | Common Stock |
| Mark Christopher Murray | EVP, Biomaterials & AT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.20 per share. | 13 Jan 2021 | 918 | 11,458 (0%) | 0% | 29.2 | 26,806 | Common Stock |
| James Bramwell | EVP, Strategic Partners | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 11 Jan 2021 | 2,505 | 116,430 (0%) | 0% | 30 | 75,150 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2021 | 162,248 | 162,250 | - | - | Stock Options (Right to Buy) | |
| Gerard Brophy | EVP, Biopharma Production | Sale of securities on an exchange or to another person at price $ 30.04 per share. | 11 Jan 2021 | 162,248 | 178,515 (0%) | 0% | 30.0 | 4,873,930 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.20 per share. | 11 Jan 2021 | 216,332 | 394,847 (0%) | 0% | 23.2 | 5,018,902 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.20 per share. | 11 Jan 2021 | 162,248 | 340,763 (0%) | 0% | 23.2 | 3,764,154 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Sale of securities on an exchange or to another person at price $ 30.08 per share. | 11 Jan 2021 | 216,332 | 178,515 (0%) | 0% | 30.1 | 6,507,267 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Sale of securities on an exchange or to another person at price $ 27.24 per share. | 06 Jan 2021 | 11,509 | 178,515 (0%) | 0% | 27.2 | 313,505 | Common Stock |
| Thomas A. Szlosek | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.15 per share. | 02 Jan 2021 | 8,135 | 257,999 (0%) | 0% | 28.1 | 229,000 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2021 | 59,418 | 118,835 | - | - | Stock Options (Right to Buy) | |
| Gerard Brophy | EVP, Biopharma Production | Sale of securities on an exchange or to another person at price $ 27.84 per share. | 02 Jan 2021 | 59,418 | 190,024 (0%) | 0% | 27.8 | 1,654,197 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.45 per share. | 02 Jan 2021 | 59,418 | 249,442 (0%) | 0% | 18.4 | 1,096,262 | Common Stock |
| Gerard Brophy | EVP, Biopharma Production | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.15 per share. | 02 Jan 2021 | 6,559 | 190,024 (0%) | 0% | 28.2 | 184,636 | Common Stock |
| Frederic Vanderhaegen | EVP, Europe | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.15 per share. | 02 Jan 2021 | 1,017 | 236,414 (0%) | 0% | 28.2 | 28,629 | Common Stock |
| Michael Wondrasch | EVP & CIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.15 per share. | 02 Jan 2021 | 4,083 | 149,974 (0%) | 0% | 28.1 | 114,936 | Common Stock |
| James Bramwell | EVP, Strategic Partners | Sale of securities on an exchange or to another person at price $ 27.14 per share. | 21 Dec 2020 | 10,020 | 117,768 (0%) | 0% | 27.1 | 271,943 | Common Stock |
| Christi Shaw | Director | Sale of securities on an exchange or to another person at price $ 26.68 per share. | 11 Dec 2020 | 14,286 | 11,319 (0%) | 0% | 26.7 | 381,150 | Common Stock |
| Michael Stubblefield | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Dec 2020 | 400,000 | 400,000 (0%) | 0% | 0 | Common Stock | |
| Michael Stubblefield | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Dec 2020 | 400,000 | 1,447,265 (0%) | 0% | 0 | Common Stock | |
| Michael Stubblefield | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.60 per share. | 04 Dec 2020 | 210,369 | 1,945,717 (0%) | 0% | 1.6 | 336,590 | Common Stock |
| Michael Stubblefield | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.60 per share. | 04 Dec 2020 | 880,601 | 2,147,536 (0%) | 0% | 1.6 | 1,408,962 | Common Stock |
| Michael Stubblefield | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 27.08 per share. | 04 Dec 2020 | 412,188 | 1,735,348 (0%) | 0% | 27.1 | 11,162,051 | Common Stock |
| Michael Stubblefield | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2020 | 201,369 | 0 | - | - | Stock Options (Right to Buy) | |
| Michael Stubblefield | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2020 | 880,601 | 201,369 | - | - | Stock Options (Right to Buy) | |
| Michael Stubblefield | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 27.45 per share. | 04 Dec 2020 | 98,452 | 1,847,265 (0%) | 0% | 27.4 | 2,702,507 | Common Stock |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2020 | 50,000 | 100,160 | - | - | Stock Options (Right to Buy) | |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.60 per share. | 05 Oct 2020 | 50,000 | 201,671 (0%) | 0% | 1.6 | 80,000 | Common Stock |
| Devashish Ohri | EVP, IMEA | Sale of securities on an exchange or to another person at price $ 23.34 per share. | 05 Oct 2020 | 50,000 | 151,671 (0%) | 0% | 23.3 | 1,167,000 | Common Stock |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2020 | 18,440 | 0 | - | - | Stock Options (Right to Buy) | |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2020 | 35,000 | 150,160 | - | - | Stock Options (Right to Buy) | |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.60 per share. | 05 Oct 2020 | 18,440 | 170,111 (0%) | 0% | 1.6 | 29,504 | Common Stock |
| Devashish Ohri | EVP, IMEA | Sale of securities on an exchange or to another person at price $ 23.53 per share. | 05 Oct 2020 | 18,440 | 151,671 (0%) | 0% | 23.5 | 433,893 | Common Stock |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.60 per share. | 05 Oct 2020 | 35,000 | 186,671 (0%) | 0% | 1.6 | 56,000 | Common Stock |
| Devashish Ohri | EVP, IMEA | Sale of securities on an exchange or to another person at price $ 23.47 per share. | 05 Oct 2020 | 35,000 | 151,671 (0%) | 0% | 23.5 | 821,450 | Common Stock |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.60 per share. | 16 Sep 2020 | 35,000 | 186,671 (0%) | 0% | 1.6 | 56,000 | Common Stock |
| Devashish Ohri | EVP, IMEA | Sale of securities on an exchange or to another person at price $ 23.02 per share. | 16 Sep 2020 | 35,000 | 151,671 (0%) | 0% | 23.0 | 805,700 | Common Stock |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2020 | 35,000 | 18,440 | - | - | Stock Options (Right to Buy) | |
| Justin Miller | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 21.17 per share. | 08 Sep 2020 | 22,887 | 113,507 (0%) | 0% | 21.2 | 484,518 | Common Stock |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.60 per share. | 30 Jul 2020 | 35,000 | 186,671 (0%) | 0% | 1.6 | 56,000 | Common Stock |
| Devashish Ohri | EVP, IMEA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2020 | 35,000 | 53,440 | - | - | Stock Options (Right to Buy) | |
| Devashish Ohri | EVP, IMEA | Sale of securities on an exchange or to another person at price $ 21.37 per share. | 30 Jul 2020 | 35,000 | 151,671 (0%) | 0% | 21.4 | 747,950 | Common Stock |
| Jo Natauri | Director | Purchase of securities on an exchange or from another person at price $ 17.10 per share. | 11 Jun 2020 | 1,910 | 58,885,252 (10%) | 0% | 17.1 | 32,661 | Common Stock, par value $0.01 per share |
| Jo Natauri | Director | Sale of securities on an exchange or to another person at price $ 16.80 per share. | 11 Jun 2020 | 20 | 58,881,208 (10%) | 0% | 16.8 | 336 | Common Stock, par value $0.01 per share |
| Jo Natauri | Director | Purchase of securities on an exchange or from another person at price $ 16.80 per share. | 11 Jun 2020 | 20 | 58,881,228 (10%) | 0% | 16.8 | 336 | Common Stock, par value $0.01 per share |
| Jo Natauri | Director | Purchase of securities on an exchange or from another person at price $ 16.84 per share. | 11 Jun 2020 | 151 | 58,881,889 (10%) | 0% | 16.8 | 2,543 | Common Stock, par value $0.01 per share |
| Jo Natauri | Director | Sale of securities on an exchange or to another person at price $ 16.84 per share. | 11 Jun 2020 | 151 | 58,881,738 (10%) | 0% | 16.8 | 2,543 | Common Stock, par value $0.01 per share |
| Jo Natauri | Director | Sale of securities on an exchange or to another person at price $ 17.75 per share. | 11 Jun 2020 | 300 | 58,881,411 (10%) | 0% | 17.8 | 5,325 | Common Stock, par value $0.01 per share |
| Jo Natauri | Director | Purchase of securities on an exchange or from another person at price $ 17.75 per share. | 11 Jun 2020 | 300 | 58,881,711 (10%) | 0% | 17.8 | 5,325 | Common Stock, par value $0.01 per share |
| Jo Natauri | Director | Sale of securities on an exchange or to another person at price $ 17.38 per share. | 11 Jun 2020 | 29 | 58,881,433 (10%) | 0% | 17.4 | 504 | Common Stock, par value $0.01 per share |
| Jo Natauri | Director | Purchase of securities on an exchange or from another person at price $ 17.38 per share. | 11 Jun 2020 | 29 | 58,881,462 (10%) | 0% | 17.4 | 504 | Common Stock, par value $0.01 per share |
| Jo Natauri | Director | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 11 Jun 2020 | 2 | 58,881,467 (10%) | 0% | 18 | 36 | Common Stock, par value $0.01 per share |
| Jo Natauri | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 11 Jun 2020 | 2 | 58,881,469 (10%) | 0% | 18 | 36 | Common Stock, par value $0.01 per share |